(Q43503967)

24 November 2017

title

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma (English)

1 reference

24 November 2017

0 references

Juliusson G

1

1 reference

24 November 2017

Celsing F

2

1 reference

24 November 2017

Turesson I

3

1 reference

24 November 2017

Lenhoff S

4

1 reference

24 November 2017

Adriansson M

5

1 reference

24 November 2017

Malm C

6

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

British Journal of Haematology

24 November 2017

published in

1 reference

24 November 2017

volume

109

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

89-96

1 reference

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01983.X

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01983.X

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01983.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01983.X

10.1046/J.1365-2141.2000.01983.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference